Novavax, Inc. v GlaxoSmithKline Biologicals SA

Link copied
Case Copied 79 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Novavax, Inc. v GlaxoSmithKline Biologicals SA [2018] APO 84

Patent Application:                   2012211278

Title:RSV immunization regimen

Patent Applicant:  GlaxoSmithKline Biologicals SA

Opponent:  Novavax, Inc

Delegate:  D. S. Triffett

Decision Date:  23 November 2018

Hearing Date:  31 August 2018, in Canberra

Catchwords:  PATENTS – section 59 opposition to grant of a patent – manner of manufacture – lack of manner of manufacture not established – novelty – lack of novelty not established – inventive step – evidence does not establish that a person skilled in the art would ascertain patent documents - lack of inventive step not established – full description – lack of full description not established – best method of performance – lack of best method of performance not established

Representation:  Counsel for the applicant:  Mr Chris Burgess

Patent attorney for the applicant: Mr Steve Gledhill and Dr Lee Miles of FB Rice        

Counsel for the opponent:  Mr Ian Horak 

Patent attorney for the opponent:  Dr Tom Gumley and Dr Catherine Windbanks of FPA Patent Attorneys Pty Ltd.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:         2012211278

Title:  RSV immunization regimen

Patent Applicant:            GlaxoSmithKline Biologicals SA.

Date of Decision:            23 November 2018

DECISION

The opposition fails on all grounds.  Subject to appeal, I direct that the application proceed to grant.

I award costs according to Schedule 8 against Novovax, Inc.

REASONS FOR DECISION

Background

  1. Patent application 2012211278 in the name of GlaxoSmithKline Biologicals SA (the applicant) was advertised as accepted on 10 November 2016.  Novavax, Inc (the opponent) opposed the grant of a patent under s 59 of the Patents Act 1990 (Cth)(the Patents Act). 

The opposition

  1. The statement of grounds and particulars identified seven grounds of opposition: manner of manufacture, novelty, inventive step, utility, full description, clarity and fair basis.  At the hearing, only four grounds were pressed: manner of manufacture, novelty, inventive step and full description.

  1. The parties relied upon evidence by several declarants.  Evidence in support consists of declarations by John Lowenthal (Lowenthal-1 and Lowenthal-2), Nigel Crawford (Crawford-1 and Crawford-2), and Catherine Windbanks (Windbanks).  Evidence in answer consists of a declaration by Paul Young (Young).  Evidence in reply consists of declarations by John Lowenthal (Lowenthal-3) and Nigel Crawford (Crawford-3).

  1. The request for examination in relation to the patent application was filed on 12 April 2013.  As a consequence, the substantive amendments of the Patents Act brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the opposed application.  This includes the amendment to s 60(3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition has been made out.  Instead, the onus of proof in this opposition proceeding lies with the opponent, who must establish that it is clear that a valid patent cannot be granted.[1]

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novavax, Inc. v GlaxoSmithKline Biologicals SA and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] APO 84
Decision Date

CaseChat Overview and Summary

The Australian Patent Office rejected all grounds of opposition in the application for a patent for a novel immunisation regimen against respiratory syncytial virus (RSV) in infants. The applicant, GlaxoSmithKline Biologicals SA, had applied for a patent on a method for providing protective immunity against RSV in an infant. The method involved administering a first anti-RSV immune response inducing composition comprising an RSV F glycoprotein to a pregnant female and administering a second anti-RSV immune response inducing composition comprising an RSV F glycoprotein to the infant born from the pregnancy at about 4 months old or younger. The opponent, Novavax, Inc., opposed the grant of the patent on various grounds, including lack of novelty, lack of inventive step, lack of full description, and lack of best method of performance. However, the Delegate of the Commissioner of Patents, D. S. Triffett, found that the opponent had not established that any of the claims lacked novelty, inventive step, full description, or best method of performance. The Delegate also found that the substance of the claims was a therapeutic method involving a two-step vaccination regimen, which was a manner of manufacture within the meaning of s 18(1)(a) of the Patents Act. The opposition failed on all grounds, and the Delegate directed that the application proceed to grant. The Delegate awarded costs to the applicant according to Schedule 8.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.